Guangzhou Joyo Pharma Co., Ltd
Clinical trials sponsored by Guangzhou Joyo Pharma Co., Ltd, explained in plain language.
-
New drug takes aim at ROS1-Positive lung cancer in Head-to-Head trial
Disease control Not yet recruitingResearchers are comparing an experimental oral drug called JYP0322 with crizotinib in adults who have not yet received treatment for ROS1-positive locally advanced or metastatic non-small cell lung cancer. The phase III trial aims to see which drug keeps cancer from worsening lon…
Phase 3 • Sponsor: Guangzhou JOYO Pharma Co., Ltd • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New hope for ROS1-Positive lung cancer: JYP0322 takes on chemo
Disease control Not yet recruitingThis Phase 3 trial compares a new drug called JYP0322 with standard platinum-based chemotherapy in 207 people with advanced ROS1-positive non-small cell lung cancer who have already been treated with ROS1-targeted therapy. The main goal is to see if JYP0322 delays cancer growth b…
Phase 3 • Sponsor: Guangzhou JOYO Pharma Co., Ltd • Aim: Disease control
Last updated Jun 26, 2026 19:19 UTC